REGENXBIO Inc. Files Definitive Proxy Statement (DEF 14A)

TL;DR

<b>REGENXBIO Inc. has filed its Definitive Proxy Statement (DEF 14A) detailing executive compensation and equity award valuations for the fiscal years 2020-2023.</b>

AI Summary

REGENXBIO Inc. (RGNX) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. REGENXBIO Inc. filed a Definitive Proxy Statement (DEF 14A) on April 4, 2024. The filing covers the fiscal year ending December 31, 2023. Key data points relate to the fair value of equity awards granted and vested during the years 2020-2023. Specific details include changes in fair value for both PEO and Non-PEO members. The company's principal executive offices are located at 9804 Medical Center Drive, Rockville, MD 20850.

Why It Matters

For investors and stakeholders tracking REGENXBIO Inc., this filing contains several important signals. This filing provides transparency into the company's executive compensation structure and the valuation of equity awards, which can influence investor perception of management alignment and future dilution. Understanding the fair value changes of equity awards helps investors assess the potential impact on earnings per share and the overall cost of employee compensation.

Risk Assessment

Risk Level: — REGENXBIO Inc. shows moderate risk based on this filing. The filing is a routine DEF 14A, providing standard disclosures on executive compensation and equity awards, with no immediate financial or operational red flags.

Analyst Insight

Investors should review the detailed breakdown of equity award valuations and changes to understand the potential dilutive effects and the company's compensation strategy.

Key Numbers

• 2024-04-04 — Filing Date (DEF 14A filing date)
• 2023-12-31 — Fiscal Year End (Period of report)
• 2020-2023 — Reporting Period for Equity Awards (Years for which equity award fair value data is presented)

Key Players & Entities

• REGENXBIO Inc. (company) — Filer of the DEF 14A
• 2024-04-04 (date) — Filing date of the DEF 14A
• 2023-12-31 (date) — Fiscal year end covered by the filing
• 9804 Medical Center Drive, Rockville, MD 20850 (address) — Business and mailing address of REGENXBIO Inc.

FAQ

Industry Context

REGENXBIO Inc. operates in the biotechnology sector, focusing on gene therapy.

Regulatory Implications

The filing is a DEF 14A, a standard SEC filing required for public companies soliciting proxies for annual meetings, ensuring transparency in corporate governance and executive compensation.

What Investors Should Do

1. Review the detailed tables on equity awards granted, vested, and their fair value changes.
2. Analyze the compensation of named executive officers (if disclosed in the full filing).
3. Assess the potential dilutive impact of equity awards on shareholders.

Key Dates

• 2024-04-04: Filing of DEF 14A — Provides details on executive compensation and equity awards for the fiscal year ending 2023.

Year-Over-Year Comparison

This is a DEF 14A filing, which typically follows a regular schedule. Specific year-over-year comparisons of compensation or equity award values would require access to previous filings.

Key Financial Figures

• $300 million — cial Strength We ended 2023 with over $300 million in cash, cash equivalents and marketabl
• $131 million — ring in which we received approximately $131 million of net proceeds. Corporate Governance

Filing Documents

• rgnx-20240404.htm (DEF 14A) — 1200KB
• img150427478_0.jpg (GRAPHIC) — 19KB
• img150427478_1.jpg (GRAPHIC) — 30KB
• img150427478_2.jpg (GRAPHIC) — 26KB
• img150427478_3.jpg (GRAPHIC) — 371KB
• img150427478_4.jpg (GRAPHIC) — 185KB
• img150427478_5.jpg (GRAPHIC) — 173KB
• img150427478_6.jpg (GRAPHIC) — 206KB
• img150427478_7.jpg (GRAPHIC) — 460KB
• img150427478_8.jpg (GRAPHIC) — 196KB
• 0000950170-24-041805.txt (&nbsp;) — 5679KB
• rgnx-20240404.xsd (EX-101.SCH) — 21KB
• rgnx-20240404_htm.xml (XML) — 191KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 26

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 49 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 52 QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND VOTING 53 OTHER MATTERS 58 CONTACT INFORMATION FOR QUESTIONS AND ASSISTANCE WITH VOTING 59 i REGENXBIO Inc. 9804 Medical Center Drive Rockville, MD 20850 PROXY STATEMENT This Proxy Statement is furnished in connection with the solicitation of proxies to be voted at the 2024 Annual Meeting of Stockholders (the "Annual Meeting") of REGENXBIO Inc., which will be held on May 31, 2024, at 9:00 a.m. local time at the Company's offices located at 9804 Medical Center Drive, Rockville, Maryland 20850. When this Proxy Statement refers to "REGENXBIO," the "Company," "we," "us" or "our," it is referring to REGENXBIO Inc. We are making this Proxy Statement and our Annual Report on Form 10K for the fiscal year ended December 31, 2023 (the "Annual Report") available to stockholders at www.proxyvote.com. On or about April 4, 2024, we will begin mailing to our stockholders a Notice of Internet Availability of Proxy Materials (the "Notice") containing instructions on how to access and review this Proxy Statement and the Annual Report. The Notice also instructs you how you may submit your proxy over the internet or via telephone. If you would like to receive a printed copy of our proxy materials, you should follow the instructions for requesting those materials included in the Notice. 2 PROXY STATEMENT EXECUTIVE SUMMARY This summary highlights information contained elsewhere in this Proxy Statement. This summary does not contain all of the information you should consider. Please read the entire Proxy Statement carefully before voting. Voting Overview and Vote Recommendations of the Board - Items of Business Election of Directors: Please vote "For" each nominee (page 6 ) Director nominees have the right mix of experience, qualifications and skills and represent a mix of

View Full Filing

View this DEF 14A filing on SEC EDGAR